Last reviewed · How we verify

OBE2109 — Competitive Intelligence Brief

OBE2109 (OBE2109) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective progesterone receptor modulator (SPRM). Area: Gynecology / Reproductive Health.

phase 3 Selective progesterone receptor modulator (SPRM) Progesterone receptor (PR) Gynecology / Reproductive Health Small molecule Live · refreshed every 30 min

Target snapshot

OBE2109 (OBE2109) — ObsEva SA. OBE2109 is a selective progesterone receptor modulator that modulates progesterone signaling to treat reproductive and gynecological disorders.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OBE2109 TARGET OBE2109 ObsEva SA phase 3 Selective progesterone receptor modulator (SPRM) Progesterone receptor (PR)
SH D 593 B (Miranova) SH D 593 B (Miranova) Bayer phase 3 Selective progesterone receptor modulator (SPRM) Progesterone receptor (PR)
PGL4001 PGL4001 PregLem SA phase 3 Selective progesterone receptor modulator (SPRM) Progesterone receptor (PR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective progesterone receptor modulator (SPRM) class)

  1. Bayer · 1 drug in this class
  2. ObsEva SA · 1 drug in this class
  3. PregLem SA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OBE2109 — Competitive Intelligence Brief. https://druglandscape.com/ci/obe2109. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: